Yayın:
Turkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based study

dc.contributor.authorKocatürk, Emek
dc.contributor.authorPırıl, Etikan
dc.contributor.authorOktay, Taşkapan
dc.contributor.authorNilgün, Atakan
dc.contributor.authorTeoman, Erdem
dc.contributor.authorSerap, Utaş
dc.contributor.authorEkin, Savk
dc.contributor.authorRafet, Koca
dc.contributor.authorŞebnem, Aktan
dc.contributor.buuauthorEmel, Bülbül Başkan
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı
dc.contributor.orcid0000-0002-0144-3263
dc.contributor.researcheridAAH-1388-2021
dc.contributor.scopusid57196063450
dc.date.accessioned2023-10-30T07:48:58Z
dc.date.available2023-10-30T07:48:58Z
dc.date.issued2017-09-09
dc.description.abstractBackground/Objectives: Chronic spontaneous urticaria (CSU) is a common skin disorder which represents a challenge both for the patients and physicians. Guidelines and treatment algorithms have been created to help physicians to ease management. Our aim was to determine Turkish dermatologists' approach to CSU with regard to treatment, search for causative factors and use of instruments to assess the quality of life and severity of the disease. Methods: This was a cross-sectional methodological study which was performed by delivery of a questionnaire including ten questions about the management of CSU. Results: Analyses of 314 questionnaires revealed that the most common first-line treatments were non-sedating antihistamines in standard doses (65.6%), while second-line treatment was updosing antihistamines (59.9%) followed by addition of sedative-antihistamines (26.4%) and systemic steroids (19.1%). Third-line treatment option was omalizumab in 35% followed by systemic steroids. Twenty-two percent of the dermatologists referred the patients to a center experienced in urticaria. Most of them were performing laboratory testing for underlying causes including thyroid function tests, C-reactive protein, thyroid auto-antibodies, stool analyses, infection markers. Urticaria activity score and chronic urticaria quality of life questionnaire were used by 30 and 13%, respectively, while 56% were using none of the instruments. Conclusion: Our study showed that the therapeutic management of Turkish dermatologists was parallel to the European Urticaria Guidelines. The high utility of omalizumab as a third line regimen improved patient care. Nevertheless there is a need for centers experienced in urticaria to refer anti-histamineresistant patients where third-line treatment options can not be implemented.
dc.identifier.citationKocatürk, E. vd. (2018). ''Turkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based study''. Dermatologica Sinica, 36(2), 70-74.
dc.identifier.doi10.1016/j.dsi.2017.09.002
dc.identifier.endpage74
dc.identifier.issn1027-8117
dc.identifier.issn2223-330X
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85031672386
dc.identifier.startpage70
dc.identifier.urihttps://doi.org/10.1016/j.dsi.2017.09.002
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1027811717300903
dc.identifier.urihttp://hdl.handle.net/11452/34656
dc.identifier.volume36
dc.identifier.wos000433284500002
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWolters Luver Medknow Publications
dc.relation.collaborationYurt içi
dc.relation.collaborationSanayi
dc.relation.journalDermatologica Sinica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDermatology
dc.subjectUrticaria
dc.subjectDermatologists
dc.subjectTherapeutics
dc.subjectDiagnosis
dc.subjectGuideline
dc.subjectChronic idiopathic urticaria
dc.subjectManagement
dc.subjectDiagnosis
dc.subjectOmalizumab
dc.subjectGuideline
dc.subjectLife
dc.subject.emtreeAntihistaminic agent
dc.subject.emtreeC reactive protein
dc.subject.emtreeOmalizumab
dc.subject.emtreeArticle
dc.subject.emtreeChronic urticaria
dc.subject.emtreeCross-sectional study
dc.subject.emtreeDermatologist
dc.subject.emtreeDisease severity
dc.subject.emtreeHealth care delivery
dc.subject.emtreeHuman
dc.subject.emtreeLaboratory test
dc.subject.emtreePractice guideline
dc.subject.emtreeQuality of life
dc.subject.emtreeQuestionnaire
dc.subject.emtreeThyroid function test
dc.subject.emtreeTreatment outcome
dc.subject.scopusOmalizumab; Urticaria; Non-Sedating Histamine H1 Antagonists
dc.subject.wosDermatology
dc.titleTurkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based study
dc.typeArticle
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Kocaturk_vd_2018.pdf
Boyut:
185.94 KB
Format:
Adobe Portable Document Format

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama